GLP-1 Drugs: Employer Considerations

Health Coverage for GLP-1 Drugs: Employer Considerations Action Items KFF’s 2025 Employer Health Benefits Survey shows that: Nearly 20% of large employers (200+ employees) cover GLP-1 drugs when used primarily for weight loss; The largest employers (5,000+ employees) are the […]

Medicare Part D Changes

Medicare Part D Changes Affecting Employer Plans for 2026 and 2027 The Medicare Part D changes implemented under the IRA continue to apply for 2026 and are codified for 2027 and beyond. Employers that sponsor prescription drug coverage for Medicare‑eligible […]

RxDC Report

  ACTION STEPS Deadline Reminder: RxDC Reports Are Due by June 1, 2026 Group health plans and health insurance issuers must annually submit detailed information on prescription drug and health care spending to the federal government. This reporting is referred […]

Medicare Part D Notice Due October 15th

Each year, Medicare Part D requires group health plan sponsors to disclose to individuals who are eligible for Medicare Part D and to the Centers for Medicare and Medicaid Services (CMS) whether the health plan’s prescription drug coverage is creditable. […]

Rehires and the ACA Employer Mandate

Brief Background Applicable large employers (generally those with more than 50 full-time and full-time equivalent employees in the prior year), are subject to the Affordable Care Act (“ACA”) employer mandate. The ACA employer mandate requires those employers to offer health […]